Operational Excellence at Scale:

Why Integrated Manufacturing is the Future Biopharmaceutical Standard

Demand for end-to-end, integrated manufacturing capabilities continues to amplify in the biopharmaceutical industry amid lingering operational and regulatory challenges.

The integrated manufacturing model positions contract development and manufacturing organisations (CDMOs) to offer three competitive advantages to their clients: simplified processes across the value chain, standardised operations for consistency, and scalable production with agility. By unifying traditionally fragmented steps into a continuum, CDMOs can turn logistical complexities into operational excellence, achieving efficiency, speed and scale without compromising quality, and ultimately earning the trust of clients, regulatory authorities and the industry.

Conventional, siloed manufacturing models are becoming outdated as the industry adapts to tighter regulations and shifting dynamics. Delays in technology transfers, cracks in data integrity and inconsistent batch outcomes not only harm operations but also erode client trust. On the other hand, CDMOs that implement end-to-end, integrated operations stay ahead of these headwinds. They can reinforce digital infrastructures through electronic manufacturing batch records (eMBRs) and manufacturing execution systems (MESs), ensure that technology transfers are both rapid and reliable, consistently release batches on time and continuously enhance their track record of client satisfaction.

Building Blocks for Integration

Integrated CDMOs combine technical and operational expertise that is built incrementally over time. Flexibility drives this buildup, starting with adaptable facility design and modular bioprocessing strategies, extending through digitalisation and anchoring in a robust quality culture, all reinforced by strategic partnerships.

- **Facility Design:** A CDMO facility must be built to evolve in a continuously changing industry landscape. Hybrid stainless-steel and single-use systems provide both long-term capacity and agile changeover readiness, while modular cleanrooms and utility backups facilitate reconfiguration without interrupting operations. By analysing cumulative process and product data, CDMOs can design facilities to accommodate mainstream industry demands and reserve modularity for specific niches, thereby avoiding costly over-engineering. The outcomes are shorter product changeovers, faster adaptability to new modalities and efficiency that scales with client demand.

- **Modular Bioprocess Strategies:** Process adaptability underpins integration. In upstream operations, process analytical technology with Raman probes monitors nutrient concentrations and cell metabolism in real time, reducing risks and triggering automated adjustments. Dual-feeding strategies combine bolus and continuous methods to accommodate a wider range of biologics, while interchangeable centrifuge bowl designs optimise yield across varying cell densities. In downstream processing, multi-train systems and adaptable chromatography columns enable parallel processing, manage complex molecules and match purification scales to client requirements, keeping projects on track despite shifting demands.

- **Digitalisation:** eMBRs and MESs lay the digital foundation for integration. By linking production floor systems with quality management, these digital advancements provide real-time traceability, ensure proactive process control and support faster batch release. Beyond compliance, digitalisation allows knowledge from one project to be captured and applied to the next. This accelerates learning cycles, reinforces traceability and issue-response capabilities, and enables data-driven flexibility across all stages of manufacturing.

- **Quality Culture:** No operation is considered minor. From labelling sampling bags to logging pH variations in a batch record, teams operate on a right-first-time principle. A culture of continuous improvement embeds regulatory readiness, translates data into actionable insights and reinforces client trust.

- **Strategic Partnerships:** Through strategic partnerships, CDMOs collect operational insights and project data, then leverage them to enhance their facility flexibility, modular strategies and optimised workflows. This iterative cycle builds an integrated infrastructure that adapts, scales and performs reliably under dynamic market and regulatory conditions.

Competitive Advantages of End-to-end Integration

The integrated manufacturing model offers three defining advantages to clients: it streamlines processes across the value chain, standardises operations for consistency and scales production with agility. Together, these benefits accelerate time-to-market, enhance operational excellence and build trust.

- **Streamlined Processes for Risk Mitigation and a Higher Batch Success Rate:** Streamlined operations stabilise production, control deviations and enforce quality oversight. Uniform training, analytics and troubleshooting protocols reduce downtime and ensure batch-to-batch consistency. Integrated validation systems synchronise process performance qualification campaigns across drug substances and drug products through shared protocols and real-time aggregated data. Parallel runs and consolidated

reporting remove handoffs, minimising manual work and sparing time for rigorous corrective actions. Unified serialisation optimises supply chain management, reduces waste and supports strategic resource planning.

- **Standardised Operations for Faster Technology Transfers and Supply:** If streamlined processes create stability, standardisation embeds consistency. Shared infrastructure, retained process knowledge and digital continuity facilitate rigorous gap assessments and, thereby, expedite technology transfers without compromise. Integrated digital systems unify documentation practices and governance frameworks, preemptively equipping CDMOs for evolving regulatory compliance. One-team rapport forged among scientists across the manufacturing, validation and quality units drives timely scale-ups, batch releases and filings according to client requirements. Speed and reliability are embedded in standardised operations.

- **Scalability for Manufacturing Readiness and First-to-market Advantage:** Scalability drives integration by turning stability and consistency into agility and resilience. CDMOs centralise supply across the clinical and commercial phases, align regulatory requirements and accelerate filings. Scalability also tackles a key industry risk: the manufacturing capacity squeeze. Without a clear path to scale, timelines slip and opportunities vanish. CDMOs address these capacity constraints by adopting standardised facility designs that enable robust technology transfers, embedding automation and digital-first operations to cut errors and deliver right-first-time production. In concert with streamlined processes and standardised strategies, scalability elevates integration to a strategic engine, securing readiness, reducing risk and enabling a first-to-market advantage.

Operational Excellence at Scale

Integrated manufacturing systems are not new in industrial production environments. The manufacturing industry, such as the automotive and aerospace sectors, has long relied on modular facilities, digitalised production records and standardised process flows to achieve manufacturing stability and efficiency across varied product lines.

The biopharmaceutical industry, however, has faced distinct constraints. The industry's evolving regulations, strict quality controls and product complexity have made the adoption of integrated manufacturing architectures slower and less uniform. Biopharmaceutical products require customised development pathways, controlled cleanroom operations and robust analytical validations at each stage. These factors have disincentivised infrastructure designs that tightly link upstream and downstream activities or that unify development with commercial scale-up.

Nonetheless, industry demand has shifted. With accelerated development timelines, the diversification of therapeutic modalities and the pressure to reduce the cost of goods sold across biologics portfolios, the need for integrated systems has heightened.

As a result, end-to-end integration becomes a strategic imperative. As pipelines grow increasingly complex and regulatory pressures intensify, CDMOs that adopt integrated models secure their roles as trusted partners. Success depends on delivering speed, scale and quality within a unified, accountable framework.

Fragmented models fail to meet today's demand for complex modalities and accelerated timelines. Integrated operations, from adaptable facilities and modular bioprocessing to digitalisation and embedded quality, create the infrastructure to perform, adapt and excel. They accelerate technology transfers, boost batch success, streamline validations, simplify supply chains and strengthen client relationships.

By consolidating technical, operational and digital capabilities, integrated CDMOs transform from outsourcing vendors into strategic partners. They deliver tangible outcomes across the value chain, enable faster delivery of life-saving therapies and define the benchmark for operational excellence at scale in biopharmaceutical manufacturing.

REFERENCES

1. International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System (Step 4/5 guideline, 2009).
2. International Council for Harmonisation (ICH). ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management (Step 4 guideline, 2019).
3. U.S. Food and Drug Administration (FDA). Process Validation: General Principles and Practices (Guidance for Industry, Jan 2011).
4. U.S. Food and Drug Administration (FDA). PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (Guidance for Industry, 2004).
5. European Commission (EudraLex, EU GMP). Annex 11: Computerised Systems (effective 2011).

Kevin Sharp

Kevin Sharp is Executive Vice President and Head of Sales & Operations at Samsung Biologics, joining in 2017. He brings extensive U.S. pharmaceutical experience, including Director of Business Development at Contract Pharmacal Corp. Previously, he spent over nine years at GSK in various business development and procurement roles for vaccines, pharmaceuticals and consumer healthcare. Kevin completed the Executive Development Program at Northwestern University's Kellogg School of Management.